The Medication(s) listed below have been approved by the Food & Drug Administration (FDA) as orphan products for treatment of this condition. There may be other products available
that are not considered orphan products.
Imatinib mesylate (Brand name: Gleevec®)
- Manufactured by
Novartis Pharmaceuticals Corp.
FDA-approved indication: Treatment of adult patients with hypereosinophic syndrome (HES) and/or chronic eosinophilic leukemia (CEL) who have the FIP1L1-PDGFRÎ± fusion kinase
National Library of Medicine Drug Information Portal